The Galleri test has a 76.3% sensitivity in cancers that cause two-thirds of cancer deaths in the US. It does cover the same cancers as cancers covered by BD1. However, sensitivity for BD1 assays is higher. i.e better at finding those with the disease. This may make the Galleri test less a cceptable. A negative test for both companies wouldn't be able to rule out the disease since they are both not 100% but BD1 is less likely.
In the world of cancer diagnosis, false negatives are not good. BD1 is the better product IMO but may come with higher false positives since BD1 specificity is lower than the Galleri test.
Sensitivity: the ability of a test to correctly identify patients with a disease. Specificity: the ability of a test to correctly identify people without the disease.
BD1 Price at posting:
$1.31 Sentiment: Hold Disclosure: Held
